1. Scrip
  2. >>Business

Biotech Drives Base Editing Into Clinic As Big Pharma Looks On

 
• By Ayisha Sharma

Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.  

Base Editing Enables A Specific Base-Pair Change Without Breaking The DNA Double Strand. • Source: Alamy

Base editing therapies are set to enter the clinic for the first time, driven by small biotech firms as big pharma largely plays it safe by developing more mature editing technologies.

Beam Therapeutics Inc.’ IND for its lead asset, BEAM-101, in sickle cell disease (SCD) was cleared by the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.